Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $28.00 at Citizens Jmp

Intellia Therapeutics (NASDAQ:NTLA) had its price objective hoisted by Citizens Jmp from $21.00 to $28.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a market outperform rating on the stock.

A number of other equities research analysts have also issued reports on the company. Barclays dropped their price target on Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, November 7th. JPMorgan Chase & Co. reissued an “underweight” rating and set a $5.00 price objective (down from $12.00) on shares of Intellia Therapeutics in a research note on Friday, November 7th. Evercore set a $8.00 target price on Intellia Therapeutics and gave the company an “in-line” rating in a report on Tuesday, November 11th. Oppenheimer set a $27.00 target price on Intellia Therapeutics in a research note on Friday, November 7th. Finally, KeyCorp set a $25.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, January 28th. Ten research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Hold” and an average price target of $19.14.

Intellia Therapeutics Stock Down 11.9%

Shares of NASDAQ NTLA opened at $13.60 on Tuesday. The firm has a 50-day simple moving average of $12.09 and a 200-day simple moving average of $13.10. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -3.55 and a beta of 2.10. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.16. The company had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. Intellia Therapeutics’s revenue was up 78.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.27) EPS. As a group, equities research analysts expect that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 34,146 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the sale, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at approximately $9,332,852.19. This trade represents a 3.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares in the company, valued at $907,488.93. The trade was a 7.95% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is currently owned by insiders.

Institutional Trading of Intellia Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Contrarius Group Holdings Ltd lifted its stake in Intellia Therapeutics by 279.4% during the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after purchasing an additional 4,337,428 shares in the last quarter. ARK Investment Management LLC grew its stake in shares of Intellia Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after buying an additional 2,288,146 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Intellia Therapeutics by 17.8% in the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after buying an additional 1,965,181 shares during the period. State Street Corp lifted its stake in Intellia Therapeutics by 29.1% during the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock worth $57,705,000 after acquiring an additional 1,447,967 shares in the last quarter. Finally, Jupiter Asset Management Ltd. acquired a new position in Intellia Therapeutics during the 3rd quarter worth about $23,519,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics News Summary

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.